2017 American Transplant Congress
Understanding the Role of Induction Agents in Older versus Younger Kidney Transplant Recipients.
Johns Hopkins University, Baltimore, MD
Background: There has been an increase in the number of older (over 65) KT recipients. Aging-related changes such as differences in immune senescence may influence…2017 American Transplant Congress
Triptolide Alleviating Acute Antibody Mediated Rejection by Inhibition of B Cell Activation in Presensitized Recipients.
Backgroud: Acute antibody mediated rejection (AMR), resistant to most anti-rejection therapy, is main cause for renal graft loss. Triptolide(TPL) had been reported as a promising…2017 American Transplant Congress
Kidney Transplantation Outcomes from Donors with Acute Kidney Injury.
Abdominal Transplant Surgery, Montefiore Medical Center, Bronx, NY
Background- Organ scarcity and increased waiting times for kidney transplantation has led the transplant community to utilize more sub-optimal organs while continuing providing survival benefit…2017 American Transplant Congress
Increasing Living Donation by Implementing the Kidney Coach Program.
Recanati Miller Transplantation Institute, Mount Sinai Hospital, New York, NY
Introduction: It is firmly established that for patients requiring transplant, living donor kidney transplantation (LDKT) is better than deceased donor transplantation. However, recipients find it…2017 American Transplant Congress
Pregnancy Outcomes in Female Kidney Transplant Recipients Using Assisted Fertility Methods.
The purpose of this study was to analyze pregnancy and transplant outcomes in female kidney recipients who used fertility medications alone (FM), intrauterine insemination (IUI),…2017 American Transplant Congress
Impact of Type 2 Surgical Injuries in Postmortem Donor Kidneys on the Post-Transplant Outcomes When Compared to Mate Non-Injured Kidney from the Same Donor.
Introduction - While damage to the procured organ is rare with organ loss being approximately 0.3% of procured organs, loss of potential transplantable organs does…2017 American Transplant Congress
Survival Benefit of Kidney and/or Pancreas Transplantation for Patients with Type 1 Diabetes in the United States.
Study Purpose: The purpose of this study was to determine the survival benefit of pancreas and/or kidney transplants as reported over a 28-year time period…2017 American Transplant Congress
CD19+CD38hiCD24hi Immature Transitional B Cells in PBMCs of Tolerant Kidney Recipients of Facilitating Cell-Enriched Hematopoietic Stem Cells and Renal Allografts.
CD19+CD38hiCD24hi immature transitional B cells may represent a biomarker for transplantation tolerance in kidney transplant (KTx) recipients (Cherukuri A, et al. J Am Soc Nephrol.…2017 American Transplant Congress
Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.
While conversion from ciclosporin to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomized-controlled trial the safety and tolerability of…2017 American Transplant Congress
Comparison of Long Term Renal Function Outcomes for Everolimus (EVR) vs. Sirolimus (SIR) vs. Mycophenolate Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant (Ktx).
MPA or mammalian target of rapamycin inhibitors (mTORi [EVR or SIR]) in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine) are used for maintenance…
- « Previous Page
- 1
- …
- 392
- 393
- 394
- 395
- 396
- …
- 531
- Next Page »